Genocea's cautionary tale: avoid inhibitory neoantigens in vaccines

Genocea shows targeting inhibitor neoantigens can abrogate vaccine-mediated protection

Genocea’s SITC presentations bolstered its case for screening out inhibitory neoantigens from cancer vaccines by suggesting the peptides play a role in checkpoint inhibitor resistance and promote disease progression.

One of the keys to designing effective personalized cancer vaccines is the selection

Read the full 411 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE